Biotech: Page 10
-
NIAID. (2023). "Influenza A virus" [Micrograph]. Retrieved from Flickr.
Cidara stock soars as antiviral drug succeeds in flu study
Company shares doubled on Phase 2 study results suggesting its drug could become an alternative to vaccines for flu prevention.
By Delilah Alvarado • June 23, 2025 -
Courtesy of Illumina
Illumina to buy SomaLogic in deal worth up to $425M
Illumina expects that adding SomaLogic will aid its “multiomics” business strategy and strengthen the value of its gene sequencing products.
By Susan Kelly • June 23, 2025 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Prothena to lay off majority of staff; Zealand shares obesity drug data
Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a dual-acting obesity drug and Biogen kicked off a new late-stage trial.
By BioPharma Dive staff • June 20, 2025 -
Getty Images
IPO windowA longer ‘winter’: Public funding slowdown heightens pressure on biotech startups
A dramatic pullback in public biotech investment catalyzed by economic and regulatory upheaval is putting even more stress on startups navigating a yearslong downturn.
By Gwendolyn Wu • June 20, 2025 -
Permission granted by Gilead Sciences
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.
By Delilah Alvarado • June 18, 2025 -
Getty Images
Obesity drugsScholar Rock drug preserves muscle in obesity trial
While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the company may look for a partner in obesity while focusing on rare diseases.
By Kristin Jensen • June 18, 2025 -
Permission granted by Cardiff University
Brain drug revivalDraig, a brain drug startup, debuts with $140M to treat depression
The funds will support Phase 2 testing of a drug the company believes to be able to safely home in on AMPA receptors, an emerging but unproven depression target.
By Gwendolyn Wu • June 18, 2025 -
Permission granted by Actio Bio
A startup banks $66M to pursue ‘inclusive precision medicine’
With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of disease-causing genetic mutations in conditions like epilepsy and Charcot-Marie-Tooth disease.
By Gwendolyn Wu • June 18, 2025 -
Getty Images
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, Intellia revealed new data and Lilly beefed up an online service offering access to Zepbound.
By BioPharma Dive staff • June 17, 2025 -
Getty Images
Roche, waving off study failures, commits to Phase 3 trials for Parkinson’s drug
The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed in two earlier studies that missed their main goals.
By Jonathan Gardner • June 16, 2025 -
Getty Images
Sage, following setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.
By Delilah Alvarado • June 16, 2025 -
Kayla Bartkowski via Getty Images
FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
A “heavy workload” and “limited resources” have left the agency unable to meet a June 17 deadline to approve a therapy Kalvista has been developing for hereditary angioedema.
By Ben Fidler • June 16, 2025 -
Courtesy of CureVac AG
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.
By Jonathan Gardner • June 13, 2025 -
Jacob Bell/BioPharma Dive
VaccinesModerna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s been significantly impacted by the recent changes in FDA and HHS leadership.
By Delilah Alvarado • June 13, 2025 -
Getty Images
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed cashed in on a stock surge and Third Harmonic kicked off a drug auction.
By Ben Fidler • June 13, 2025 -
Courtesy of EQT Life Sciences
SpliceBio lands $135M for a new kind of eye gene therapy
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
By Gwendolyn Wu • June 11, 2025 -
Getty Images
Insmed surges on lung drug data; Recursion cuts staff
Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations. Elsewhere, Recursion is laying off 20% of its workforce and Gilead halted several HIV studies.
By BioPharma Dive staff • June 11, 2025 -
Getty Images
FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche
The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already struggled to grow sales.
By Ben Fidler • June 11, 2025 -
Getty Images
Scorpion, fresh off Lilly deal, spins out startup Antares
Five months after selling a cancer drug to Lilly for up to $2.5 billion, Scorpion has debuted a successor company led by its former management team to chase “previously inaccessible” drug targets.
By Ben Fidler • June 10, 2025 -
Courtesy of National Resilience; Business Wire
National Resilience, a well-funded manufacturing startup, to scale back operations
The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”
By Gwendolyn Wu • June 10, 2025 -
Getty Images
Biotech zombiesConcentra to acquire Elevation in bid to eliminate another biotech ‘zombie’
The offer is the latest in a series of deals by Concentra, an entity controlled by Tang Capital Partners, to buy struggling biotechs and shut them down.
By Ben Fidler • June 9, 2025 -
Spencer Platt via Getty Images
Obesity drugsMetsera shares climb on early data for amylin-targeting obesity shot
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, might have effects that last at least four weeks.
By Jonathan Gardner • Updated June 9, 2025 -
Courtesy of Omada Health
Omada goes public in second recent digital health IPO
The chronic condition management company’s debut comes weeks after another digital health company, Hinge Health, went public. The IPOs are a “promising bellwether” for the sector, one expert said.
By Emily Olsen • June 9, 2025 -
Getty Images
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update
Late-stage results Otsuka presented in IgA nephropathy triggered a sell-off in Vera shares. Elsewhere, investors scrutinized Regenxbio’s Duchenne data and a brain drug study failed.
By BioPharma Dive staff • June 6, 2025 -
Getty Images
Immune resetCullinan doubles down on bispecifics for autoimmune disease with Genrix deal
The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions.
By Kristin Jensen • June 5, 2025
Previous
